From the Hypertension and Vascular Disease Center, Wake Forest University
School of Medicine, Winston-Salem, NC (K.Y., S.N.I., M.C.C., C.M.F.); and Max
Delbruck Center for Molecular Medicine, Berlin-Buch, Germany (D.G.).
Correspondence to Carlos M. Ferrario, MD, Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC 27157.
Abstract—We determined the
mechanism accounting for the removal and metabolism of
angiotensin-(1–7) [Ang-(1–7)] in 21
anesthetized spontaneously hypertensive (SHR), 18 age-matched
normotensive Sprague-Dawley (SD), and 36 mRen-2
transgenic (TG+) rats. Animals of all 3 strains were
provided with tap water or tap water containing losartan,
lisinopril, or a combination of lisinopril and
losartan for 2 weeks. On the day of the experiment, Ang-(1–7)
was infused for a period of 15 minutes at a rate of 278 nmol ·
kg-1 · min-1. After this time, samples
of arterial blood were collected rapidly at regular
intervals for the assay of plasma Ang-(1–7) levels by
radioimmunoassay. Infusion of Ang-(1–7) had a minimal effect on
vehicle-treated SD rats but elicited a biphasic pressor/depressor
response in vehicle-treated SHR and TG+ rats. In
lisinopril-treated rats, Ang-(1–7) infusion increased
blood pressure, whereas losartan treatment abolished the
pressor component of the response without altering the secondary fall
in arterial pressure. Combined treatment with
lisinopril and losartan abolished the
cardiovascular response to Ang-(1–7) in all 3 strains.
In vehicle-treated SD, SHR and TG+ the half-life
(t1/2) of Ang-(1–7) averaged 10±1, 10±1, and 9±1
seconds, respectively. Lisinopril alone or in combination
with losartan produced a statistically significant rise in the
half-life of Ang-(1–7) in all 3 strains of rats. Plasma clearance of
Ang-(1–7) was significantly greater in the untreated SD rats compared
with either the SHR or TG+ rat. Lisinopril
treatment was associated with reduced clearance of Ang-(1–7) in all 3
strains. Concurrent experiments in pulmonary membranes from SD
and SHR showed a statistically significant inhibition of
125I-Ang-(1–7) metabolism in the presence of
lisinopril. These studies showed for the first time that
the very short half-life of Ang-(1–7) in the circulation is primarily
accounted for peptide metabolism by ACE. These findings
suggest a novel role of ACE in the regulation of the production
and metabolism of the two primary active hormones of the
renin angiotensin system.
© 1998 American Heart Association, Inc.
Scientific Contributions
Converting Enzyme Determines Plasma Clearance of Angiotensin-(1–7)
Key Words: angiotensin-(1–7) • blood pressure • angiotensin-converting enzyme • lisinopril • losartan • rats, inbred SHR • rats, transgenic
This article has been cited by other articles:
 |
|
 |
|
  L. D. Kluskens, S. A. Nelemans, R. Rink, L. de Vries, A. Meter-Arkema, Y. Wang, T. Walther, A. Kuipers, G. N. Moll, and M. Haas Angiotensin-(1-7) with Thioether Bridge: An Angiotensin-Converting Enzyme-Resistant, Potent Angiotensin-(1-7) Analog J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 849 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Hamming, H. van Goor, A. J. Turner, C. A. Rushworth, A. A. Michaud, P. Corvol, and G. Navis Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats Exp Physiol, May 1, 2008; 93(5): 631 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Tikellis, K. Bialkowski, J. Pete, K. Sheehy, Q. Su, C. Johnston, M. E. Cooper, and M. C. Thomas ACE2 Deficiency Modifies Renoprotection Afforded by ACE Inhibition in Experimental Diabetes Diabetes, April 1, 2008; 57(4): 1018 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Reyes-Engel, L. Morcillo, F. J. Aranda, M. Ruiz, M. J. Gaitan, A. Mayor-Olea, P. Aranda, and C. M. Ferrario Influence of Gender and Genetic Variability on Plasma Angiotensin Peptides Journal of Renin-Angiotensin-Aldosterone System, June 1, 2006; 7(2): 92 - 97. [Abstract] [PDF]
|
|
|
|
 |
|
 C. M. Ferrario, A. J. Trask, and J. A. Jessup Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2281 - H2290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sakima, D. B. Averill, P. E. Gallagher, S. O. Kasper, E. N. Tommasi, C. M. Ferrario, and D. I. Diz Impaired Heart Rate Baroreflex in Older Rats: Role of Endogenous Angiotensin-(1-7) at the Nucleus Tractus Solitarii Hypertension, August 1, 2005; 46(2): 333 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Modrall, J. Sadjadi, K. B. Brosnihan, P. E. Gallagher, C.-h. Yu, G. L. Kramer, K. E. Bernstein, and M. C. Chappell Depletion of Tissue Angiotensin-Converting Enzyme Differentially Influences the Intrarenal and Urinary Expression of Angiotensin Peptides Hypertension, April 1, 2004; 43(4): 849 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Stegbauer, V. Oberhauser, O. Vonend, and L. C. Rump Angiotensin-(1-7) modulates vascular resistance and sympathetic neurotransmission in kidneys of spontaneously hypertensive rats Cardiovasc Res, February 1, 2004; 61(2): 352 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Wamberg, R. R. Plovsing, N. C. F. Sandgaard, and P. Bie Effects of different angiotensins during acute, double blockade of the renin system in conscious dogs Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2003; 285(5): R971 - R980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Vauquelin, Y. Michotte, I. Smolders, S. Sarre, G. Ebinger, A. Dupont, and P. Vanderheyden Cellular targets for angiotensin II fragments: pharmacological and molecular evidence Journal of Renin-Angiotensin-Aldosterone System, December 1, 2002; 3(4): 195 - 204. [Abstract] [PDF]
|
|
|
|
|
|
I. Kucharewicz, R. Pawlak, T. Matys, D. Pawlak, and W. Buczko Antithrombotic Effect of Captopril and Losartan Is Mediated by Angiotensin-(1-7) Hypertension, November 1, 2002; 40(5): 774 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Shrimpton, A. I. Smith, and R. A. Lew Soluble Metalloendopeptidases and Neuroendocrine Signaling Endocr. Rev., October 1, 2002; 23(5): 647 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Goette, U. Lendeckel, and H. U Klein Signal transduction systems and atrial fibrillation Cardiovasc Res, May 1, 2002; 54(2): 247 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mustafa, Joo Hyung Lee, Siew Yeen Chai, A. L Albiston, S. G McDowall, and F. A. Mendelsohn Bioactive angiotensin peptides: focus on angiotensin IV Journal of Renin-Angiotensin-Aldosterone System, December 1, 2001; 2(4): 205 - 210. [PDF]
|
|
|
|
|
|
B. Tom, R. de Vries, P. R. Saxena, and A.H. J. Danser Bradykinin Potentiation by Angiotensin-(1-7) and ACE Inhibitors Correlates With ACE C- and N-Domain Blockade Hypertension, July 1, 2001; 38(1): 95 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Iyer, D. B. Averill, M. C. Chappell, K. Yamada, A. J. Allred, and C. M. Ferrario Contribution of Angiotensin-(1-7) to Blood Pressure Regulation in Salt-Depleted Hypertensive Rats Hypertension, September 1, 2000; 36(3): 417 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Tallant, D. I. Diz, and C. M. Ferrario Antiproliferative Actions of Angiotensin-(1-7) in Vascular Smooth Muscle Hypertension, October 1, 1999; 34(4): 950 - 957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Linz, P. Wohlfart, B. A Scholkens, T. Malinski, and G. Wiemer Interactions among ACE, kinins and NO Cardiovasc Res, August 15, 1999; 43(3): 549 - 561. [Full Text] [PDF]
|
|
|
|
|
|
A. J. M. Roks, P. P. van Geel, Y. M. Pinto, H. Buikema, R. H. Henning, D. de Zeeuw, and W. H. van Gilst Angiotensin-(1–7) Is a Modulator of the Human Renin-Angiotensin System Hypertension, August 1, 1999; 34(2): 296 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Traynor, T. Yang, Y. G. Huang, J. H. Krege, J. P. Briggs, O. Smithies, and J. Schnermann Tubuloglomerular feedback in ACE-deficient mice Am J Physiol Renal Physiol, May 1, 1999; 276(5): F751 - F757. [Abstract] [Full Text] [PDF]
|
|